JP2022527173A5 - - Google Patents

Info

Publication number
JP2022527173A5
JP2022527173A5 JP2021557602A JP2021557602A JP2022527173A5 JP 2022527173 A5 JP2022527173 A5 JP 2022527173A5 JP 2021557602 A JP2021557602 A JP 2021557602A JP 2021557602 A JP2021557602 A JP 2021557602A JP 2022527173 A5 JP2022527173 A5 JP 2022527173A5
Authority
JP
Japan
Prior art keywords
chain variable
seq
variable region
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527173A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024432 external-priority patent/WO2020205331A1/en
Publication of JP2022527173A publication Critical patent/JP2022527173A/ja
Publication of JP2022527173A5 publication Critical patent/JP2022527173A5/ja
Pending legal-status Critical Current

Links

JP2021557602A 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用 Pending JP2022527173A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962825955P 2019-03-29 2019-03-29
US62/825,955 2019-03-29
US201962859843P 2019-06-11 2019-06-11
US62/859,843 2019-06-11
US201962896758P 2019-09-06 2019-09-06
US62/896,758 2019-09-06
PCT/US2020/024432 WO2020205331A1 (en) 2019-03-29 2020-03-24 Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Publications (2)

Publication Number Publication Date
JP2022527173A JP2022527173A (ja) 2022-05-31
JP2022527173A5 true JP2022527173A5 (cg-RX-API-DMAC7.html) 2022-06-29

Family

ID=72667032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557602A Pending JP2022527173A (ja) 2019-03-29 2020-03-24 ヒト化抗クローディン18.2キメラ抗原受容体及びその使用

Country Status (12)

Country Link
US (1) US20220184126A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947468A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022527173A (cg-RX-API-DMAC7.html)
KR (1) KR20210144792A (cg-RX-API-DMAC7.html)
CN (1) CN113784980B (cg-RX-API-DMAC7.html)
AU (1) AU2020253792A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132201A1 (cg-RX-API-DMAC7.html)
IL (1) IL286696A (cg-RX-API-DMAC7.html)
MX (1) MX2021011887A (cg-RX-API-DMAC7.html)
SG (1) SG11202109052YA (cg-RX-API-DMAC7.html)
WO (1) WO2020205331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
WO2022122709A1 (en) * 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN115073606B (zh) * 2021-03-10 2025-05-02 上海莱馥医疗科技有限公司 一种靶向表达cldn 18.2的细胞的人源化嵌合抗原受体
CN113354739B (zh) * 2021-01-11 2022-08-23 上海莱馥医疗科技有限公司 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用
KR20240044467A (ko) 2021-08-09 2024-04-04 하버 바이오메드 (상하이) 컴퍼니 리미티드 Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Shenzhen Immunofoco Biotechnology Co., Ltd. Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
KR20250087608A (ko) * 2022-10-10 2025-06-16 메디뮨 엘엘씨 클라우딘 18.2를 표적화하는 키메라 항원 수용체로 암을 치료하는 조성물 및 방법
WO2025255276A1 (en) * 2024-06-04 2025-12-11 Fred Hutchinson Cancer Center Anti-whitlow linker binding domains and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
MX2020009326A (es) * 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2022526420A5 (cg-RX-API-DMAC7.html)
JP2022093564A5 (cg-RX-API-DMAC7.html)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2022526841A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2021528047A5 (cg-RX-API-DMAC7.html)
JP2023509196A5 (cg-RX-API-DMAC7.html)
JP2009545325A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2024531409A5 (cg-RX-API-DMAC7.html)
JP2013165711A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2020528750A5 (cg-RX-API-DMAC7.html)
CN103030695B (zh) 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2020510422A5 (cg-RX-API-DMAC7.html)
JP2016526904A5 (cg-RX-API-DMAC7.html)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2017186337A5 (cg-RX-API-DMAC7.html)
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
JP2015529641A5 (cg-RX-API-DMAC7.html)
JP2013527762A5 (cg-RX-API-DMAC7.html)